About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes

NCT00357370·23 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

AstraZeneca

With

Bristol-Myers Squibb

Age

18–75

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Males and females, 18 to 75 years old, with type 2 diabetes with inadequate glycemic control
Subjects receiving insulin and metformin and/or a thiazolidinedione
Body Mass Index \<=45.0 kg/m2
Serum creatinine \<1.5 mg/dL for men or \<1.4 mg/dL for women
No overt proteinuria (in subjects with a microalbumin/creatinine ratio ≥300 mg/g, the 24-hour urinary excretion of total protein must be \<3 g/24 hrs)

You may not be if

History of type 1 diabetes
AST and/or ALT \>2.5 times the upper limit of normal
Creatinine kinase ≥3 times the upper limit of normal
Symptoms of severely uncontrolled diabetes
History of hypoglycemic unawareness
Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases

The record

StatusCompleted

PhasePhase 2–3

Taking part163

StartedOct 2006

UpdatedMay 11, 2017

Conditions

Type 2 Diabetes

Where23

Nea Clinic
Jonesboro, Arkansas, United States
Valley Research
Fresno, California, United States
Bernstein, Richard
Greenbrae, California, United States

Clareo Health | A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes